Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24‐hour continuously monitored mean glucose and fasting β‐hydroxybutyrate levels in a phase IIa pilot study
- 18 January 2017
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 19 (6) , 814-821
Abstract
Aims: To investigate the effects of total daily insulin dose ( TDD ) reductions on 24‐hour continuously monitored mean glucose and fasting β‐hydroxybutyrate (a marker for diabetic ketosis/ketoacidosis [ DKA ]) levels, using patient‐level data from a 14‐day, pilot study of dapagliflozin in type 1 diabetes ( T1DM ). Methods: A post hoc exploratory correlation analysis was performed to determine the relationship between change in TDD and (1) 24‐hour mean glucose, assessed by continuous glucose monitoring, and (2) fasting β‐hydroxybutyrate, in 70 patients with T1DM receiving insulin and dapagliflozin (1, 2.5, 5 or 10 mg) or placebo. The pharmacodynamic effect of dapagliflozin was estimated as a virtual “insulin dose” using 24‐hour urinary glucose excretion values and a recognized insulin‐to‐carbohydrate counting technique. Results: Trends for correlations were observed between change in TDD and 24‐hour glucose (day 7: r = −0.264, P = .056) and β‐hydroxybutyrate (day 7: r = −0.187, P = .133; day 14: r = −0.274, P = .047). The pharmacodynamic effect of dapagliflozin 5 or 10 mg was estimated as equivalent to ~20% of baseline TDD . Higher mean and maximum β‐hydroxybutyrate levels were observed on days 7 and 14 in patients with a TDD reduction >20% vs ≤20%. Conclusions: Over 14 days, decreasing the insulin dose diminished the glucose‐lowering effect of dapagliflozin–insulin combination therapy and increased levels of β‐hydroxybutyrate. While insulin dose adjustments should always be individualized, these analyses suggest that, as a general rule, TDD reduction in dapagliflozin‐treated patients with T1DM should not exceed 20%, to ensure glycaemic control does not deteriorate and to mitigate the potential for an increased risk of DKA .Keywords
Funding Information
- AstraZeneca
This publication has 17 references indexed in Scilit:
- Diabetic Ketoacidosis With Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 DiabetesDiabetes Care, 2016
- Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical ProgramDiabetes Care, 2015
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 InhibitionDiabetes Care, 2015
- Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic RegistryDiabetes Care, 2015
- Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary glucose excretion in healthy subjectsDiabetes, Obesity and Metabolism, 2015
- Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot StudyDiabetes Care, 2014
- Update on developments with SGLT2 inhibitors in the management of type 2 diabetesDrug Design, Development and Therapy, 2014
- Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump Management Task ForceEndocrine Practice, 2014
- Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks?Diabetologia, 2013
- Insulin Therapy2013